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Abstract
Silver nanoparticles offer a huge potential for biomedical applications owing to their exceptional 
properties and small size. Specifically, cysteamine-capped silver nanoparticles could form the 
basis for new anticancer therapies combining the cytotoxic effect of the silver core with the 
inherent antitumor activity of cysteamine, which inhibit cancer cell proliferation and suppress 
invasion and metastasis. In addition, the capability of the cysteamine coating monolayer to 
couple a variety of active principles and targeting (bio)molecules of interest proves key to 
the tailoring of this platform in order to exploit the pathophysiology of specific tumor types. 
Nevertheless, the chain length and conformational flexibility of cysteamine, together with its 
ability to attach to the surface of silver nanoparticles via both the thiol and the amine group, have 
made the in situ synthesis of these particles an especially challenging task. Herein we report a 
solvent-assisted in situ synthesis method that solves this problem. The obtained nanoparticles 
have been fully characterized by UV–visible absorption spectroscopy, Fourier transform 
infrared spectroscopy, transmission electron microscopy, electron diffraction measurement, high 
resolution transmission electron microscopy, scanning transmission electron microscopy, energy 
dispersive x-ray spectroscopy nanoanalysis, and dynamic light scattering measurement. Our 
synthesis method achieves extremely high yield and surface coating ratio, and colloidal stability 
over a wide range of pH values including physiological pH. Additionally, we have demonstrated 
that cysteamine-capped nanoparticles obtained by this method can be conjugated to an antibody 
for active targeting of the epidermal growth factor receptor, which plays an important role in 
the pathogenesis and progression of a wide variety of tumors, and induce cell death in human 
squamous carcinoma cells. We believe this method can be readily extended to combinations of 
noble metals and longer chain primary, secondary, ternary or even quaternary aminethiols.
Keywords: cysteamine, 2-mercaptoethylamine, silver nanoparticles, DMF, targeted antitumor 
therapy, epidermal growth factor receptor
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1. Introduction
Noble metal nanoparticles offer a huge potential for bio-
medical applications due to their exceptional properties and 
their ability to be coupled to molecules and biomolecules of 
interest [1–10]. For this purpose, the most common strategy is 
to functionalize their surface with chemical groups allowing 
for subsequent coupling via self-attachment of suitable thiol 
monolayers on the growing nuclei, i.e. in situ synthesis [2–4]. 
In this sense, short-chain thiols such as cysteamine (2-mer-
captoethylamine) represent an optimal choice for functional-
ization because they do not increase particle size significantly, 
which is critically important for most biomedical applications.
Although an in situ synthesis of cysteamine-capped silver 
nanoparticles has been described [11], the initial metal con-
centrations required to obtain nanoparticles are extremely low 
and it has not been widely used so far. These initial low con-
centrations, which translate into low nanoparticle concentra-
tions, might be suitable for sensing applications [11, 12], but 
may be too low for most biomedical formulations. Therefore, 
achieving an in situ synthesis of stable cysteamine-capped 
silver nanoparticles at high nanoparticle concentrations is 
highly desirable and still remains a scientific challenge.
Cysteamine is a short chain thiol approved by the Food and 
Drug Administration (FDA) for the treatment of cystinosis 
that stands out for its broad range of applications not only 
in the biomedical field, with potential use in the treatment of 
malaria, acquired immunodeficiency syndrome, Huntington’s 
disease, or cancer, among others [13]. When coupled to nan-
oparticles, cysteamine can also act as a linker both in drug 
delivery vectors [14–22] and in bio- and chemical-sensors 
[23–31]. With regard to its anticancer activity, cysteamine has 
been proved to prevent metaplasia and carcinogenesis induced 
by radiation or chemicals [32–34], to inhibit cancer cell pro-
liferation [35], to suppress invasion and metastasis [36], and 
to induce autophagy in cancer cells [37]. Moreover, a wide 
range of nanoparticles functionalized with cysteamine have 
in fact shown antitumor activity [38–42], yet none of these 
are made up of silver despite being a cytotoxic material of 
choice. Indeed, the toxicity of silver nanoparticles has been 
widely explored in the context of bactericidal agents owing to 
their potential to overcome antibiotic resistance, and is now 
extending its potential to the development of new cancer ther-
apies [43]. Like any other chemotherapeutic cytotoxic agent, 
silver should be vectorized to the tumor cells to avoid adverse 
effects on healthy tissues. In this sense, cysteamine offers the 
advantage of acting as a linker between the silver nanopar-
ticle and the targeting agent, providing a coating layer on the 
surface of the nanoparticle made up by amino groups able to 
ensure the orientational binding of targeting antibodies, while 
providing the nanocarrier with additional and valuable anti-
tumor properties.
In this work we report a new method for the in situ syn-
thesis of cysteamine-capped silver nanoparticles. Our syn-
thesis method achieves a high yield, an extremely high surface 
coating, and exceptional colloidal stability. An additional layer 
of complexity was introduced by conjugating an antibody to 
target silver nanoparticles to cancer cells overexpressing the 
epidermal growth factor receptor (EGFR), a ‘hot’ target pro-
tein that plays an important role in the pathogenesis and pro-
gression of a wide variety of tumors.
2. Experimental
Silver nitrate, N,N-dimethylformamide (DMF) and 
2-(N-morpholino)ethanesulfonic acid (MES) were pur-
chased from Panreac. Sodium borohydride (NaBH4) was 
purchased from Sigma-Aldrich. 2-Mercaptoethylamine 
hydrochloride (cysteamine), (N-(3-dimethylaminopropyl)-
Nʹ-ethylcarbodiimide hydrochloride (EDC) and 
N-hydroxysuccinimide (NHS) were purchased from Alfa 
Aesar. Anti-EGFR (528) AF488 sc-120 (Ab) was purchased 
from Santa Cruz Biotechnology. Water was purified using a 
milli-Q (18.2 MΩ) reagent-grade water system from Millipore. 
Dialysis membranes Cellu Sep T3 (12–14 kDa) were supplied 
from Membrane Filtration Products, Inc. Prior to synthesis, all 
glassware was cleaned with aqua regia.
2.1. Synthesis of nanoparticles
Cysteamine-capped silver nanoparticles (Ag@cys) were 
synthesized by reduction of silver nitrate in the presence of 
cysteamine as capping agent, and DMF as reaction medium. 
In a typical preparation, 500 µl of an aqueous solution of 
cysteamine (0.7 mmol) and 500 µl of an aqueous solution 
of AgNO3 (0.234 mmol) were sequentially added to 20 ml 
of DMF, as reaction medium, under stirring in an ice bath. 
Afterwards, 3 ml of an aqueous solution of NaBH4 (210 mM) 
were added dropwise. The reaction mixture was stirred for 
20 min, after which Ag@cys nanoparticles were recovered by 
centrifugation (8000 rpm, 10 min), resuspended in 20 ml MES 
buffer (50 mM) and purified by dialysis against water for 48 h. 
The resulting nanoparticles were then lyophilized to obtain 
21.2  ±  0.4 mg of Ag@cys as a dark brown powder. The reac-
tion yield, calculated as the amount of Ag+ in the recovered 
nanoparticles with respect to the initial amount of Ag+ in the 
reaction, was 79%.
To determine the pH range in which Ag@cys nanoparti-
cles are stable, a set of nanoparticles was dispersed in water 
(1 mg ml−1) and the pH modified from pH 2 to 10 by adding 
appropriate amounts of an aqueous solution of NaOH (0.1 M) 
or HCl (0.1 M).
To obtain cysteamine-capped silver nanoparticles tar-
geted to the epidermal growth factor receptor (EGFR), a set 
of Ag@cys nanoparticles was conjugated to a monoclonal 
antibody to EGFR through carbodiimide-based chemistry, 
according to a protocol previously developed by our group to 
ensure the correct steric orientation of the targeting antibody 
on the nanoparticle surface [44]. Briefly, a mixture of 250 µl 
Ag@cys (1 mg ml−1, in 50 mM MES, pH 6.5), 250 µl EDC 
(5.2 mM in 50 mM MES, pH 6.5) and 2.5 ml NHS (8.7 mM 
in 50 mM MES, pH 6.5) was stirred at room temperature for 
30 min. Afterwards, 250 µl of anti-EGFR (50 µg ml−1) were 
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added and the mixture stirred for 24 h. The resulting suspen-
sion of targeting nanoparticles, namely Ag@cys@Ab, was 
centrifuged at 6000 rpm in order to wash off excess unbound 
antibody and coupling reagents. The nanoparticles were then 
resuspended in a BSA 0.1% (w/v) solution (in milli-Q water) 
and stored at 4 °C until their use in biological assays.
2.2. Characterization
Ag@cys nanoparticles were characterized by UV–vis absorp-
tion spectroscopy, Fourier transform infrared (FTIR) spectr-
oscopy, transmission electron microscopy (TEM), electron 
diffraction (ED) measurement, high resolution transmission 
electron microscopy (HRTEM), scanning transmission elec-
tron microscopy (STEM), energy dispersive x-ray (EDX) 
spectroscopy nanoanalysis and dynamic light scattering 
(DLS) measurement. FTIR spectra were recorded on a Bruker 
IFS 66/s spectrometer equipped with a DTS detector. We aver-
aged 150 scans with a scan frequency of 2.5 Hz and 3 cm−1 
resolution. The samples were prepared by depositing 100 µl 
of an aqueous suspension of nanoparticles on a silicon plate. 
The as prepared samples were allowed to dry at room temper-
ature before recording the spectra. UV–vis spectra were 
recorded on an Ocean optics spectrometer equipped with a 
HR4000 detector with quartz cuvette of 1 cm optic pass. 
One milliliter of the nanoparticles suspension was added to 
the quartz cuvette. TEM images and ED patterns were per-
formed on a 200 kV Philips CM200 microscope equipped 
with a supertwin objective lens and a LaB6 filament (point 
resolution 0.25 nm). The samples were prepared by drying a 
drop of an aqueous suspension of nanoparticles on a carbon 
coated copper grid. HRTEM and STEM images were obtained 
with a high-angle annular dark field (HAADF) detector in a 
300 kV TECNAI G2 F30 microscope with a field emission 
system (point resolution 0.2 nm). The samples were prepared 
by drying a drop of an aqueous suspension of nanoparticles 
on a carbon coated copper grid. EDX nanoanalysis was per-
formed in STEM mode and the analysis of the spectra and the 
HAADF-STEM images were done with the ES vision soft-
ware (FEI Company). The samples were prepared by drying 
a drop of an aqueous suspension of nanoparticles on a carbon 
coated copper grid. Hydrodynamic diameter and zeta poten-
tial were measured on a Zetatrac (Microtrac). Two milliliters 
of the nanoparticle suspension were added to the cavity and 
measured by DLS at room temperature (25 °C).
2.3. Cellular cytotoxicity and uptake assays
The biological behavior of nanoparticles was evaluated in the 
A431 human squamous carcinoma cell line, an epidermoid 
carcinoma target model to study the effect of therapeutic 
approaches directed to EGFR owing to the overexpression 
of this protein. Cells were cultured in roswell park memo-
rial institute (RPMI) medium supplemented with 10% fetal 
bovine serum (FBS) and 50 U ml−1 penicillin/streptomycin, 
and grown at 37 °C and 5% (v/v) CO2.
Cytotoxicity was evaluated using the in vitro Toxicology 
Assay Kit, Resazurin based (Sigma-Aldrich), according to 
the kit specifications, after inoculating cells with growing 
amounts of nanoparticles (5–100 µg ml−1, final concentra-
tion). The cell viability was expressed as a relative percentage 
compared to untreated cells and all results were expressed 
as mean  ±  standard deviation (SD). The student’s t-test was 
used to analyze the data and statistically significant differ-
ences. Only p-values smaller than 0.05 were considered as 
statistically significant. For cell uptake visualization, A431 
cells were grown on 1 mm (goldseal no.1) glass coverslips 
for 48 h in RPMI medium, supplemented as described above. 
At this stage cells were rinsed with phosphate-buffered saline 
(PBS), inoculated with culture medium containing 10 µg ml−1 
of nanoparticles and cultured for 2 h, rinsed with PBS and cul-
tured during 48 h in fresh culture medium. Cells were then 
rinsed once with PBS, fixed in 4% (w/v) paraformaldehyde 
(PFA) for 5 min at room temperature (25 °C), and permea-
bilized in 0.1% (w/v) saponin in PBS for 5 min. Cells were 
subsequently stained with Hoechst 33 342 (1 mg ml−1) and 
washed with PBS. The presence of silver nanoparticles and 
anti-EGFR was analyzed by dark field and fluorescence 
microscopy, respectively, using a Leica DM 2500 microscope 
(lens: 100×  oil).
3. Results and discussion
3.1. Synthesis and characterization of cysteamine-capped 
silver nanoparticles
We have accomplished the in situ syntheses of cysteamine-
capped silver nanoparticles by reducing silver nitrate in the 
presence of cysteamine in two different reaction media, water 
and DMF. Both selected solvents are polar, according to the 
polar nature of the reactants, but while the first is protic, the 
second is aprotic. The reduction was performed using a strong 
reducing agent, sodium borohydride, and a cysteamine:Ag 
ratio that could be held as low as 3:1 in DMF. This com-
pares favorably to the water case described in the literature 
[11], in which ratios of 40:1 were used. Additionally, another 
advantage of DMF is that the synthesis in DMF has long-term 
stability, and is reproducible. Attempts to synthesize stable 
cysteamine-capped silver nanoparticles in aqueous medium at 
a cysteamine:Ag ratio of 3:1 failed, as shown by the absence 
of the characteristic silver nanoparticle plasmon in the UV–
vis spectrum (figure 1). Instead, nanoparticles grow out of 
control due to Ostwald ripening and the sample turns grey 
immediately after the addition of the reducing agent, which 
indicates the formation of large particles of metallic silver 
(inset of figure 1).
The strong background absorption in the UV–vis spectrum 
provides further evidence for this growth. Thus, cysteamine 
fails to stabilize nanoparticles during the growth step in 
aqueous medium resulting in aggregation. Contrary to what 
happens when using water as reaction medium, Ag nanopar-
ticles synthesized in DMF exhibit a strong plasmon peaking 
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at 426 nm (figure 1), which is characteristic of silver nano-
particles and indicates that this solvent yields nanoparticles. 
Therefore, all subsequent characterization techniques were 
applied to the nanoparticles obtained using DMF as solvent, 
hereinafter Ag@cys. The fact that the synthesis is successful 
in DMF but not in water can be explained based on the nature 
of both the ligand and the solvent. It has been described that 
cysteamine is able to bind to the surface of silver through both 
the thiol and the amine group (figure 2(a)) [45]. This bidentate 
linkage necessarily leads to a decrease of the coating degree, 
a decrease in surface groups and charge, and consequently 
to a decrease in the stability of the nanoparticles. According 
to our results, DMF, as a polar aprotic solvent that stabilizes 
cationic species such as the positively charged amine group 
of cysteamine hydrochloride, hinders its interaction with the 
nanoparticle surface and promotes the interaction of the ligand 
through the thiol group (figure 2(b)), resulting in increased 
coating, as discussed later. Additionally, another remarkable 
advantage of our in situ synthesis versus ligand exchange or 
ligand addition after the synthesis, is that the presence of the 
reducing agent in the reaction medium prevents the forma-
tion of disulfide bridges initially present or that might form 
in atmospheric conditions, eliminating the need to carry out 
the functionalization of nanoparticles under inert atmosphere 
[46].
Taking into account that the stability of metal nanoparti-
cles depends to a great extent on the ionization state of their 
surface coating, the stability of Ag@cys nanoparticles should 
be influenced by the net charge of the amine layer on their 
surface and, therefore, by the pH of the dispersing medium. 
Amine groups are positively charged at low pH; but the higher 
the pH, the more uncharged groups are present, and these are 
able to form hydrogen bonds between nanoparticles inducing 
their aggregation. The exact value at which this takes place 
depends on the effective pKa of the nanoparticles, i.e. the pH 
value at which half of the groups are protonated. This value 
is, as a general rule, significantly lower than that of the free 
ligand [47]. To determine the pH range in which our colloid 
is stable and no aggregation occurs, nanoparticles were dis-
persed in water and the pH set to values from pH 2 to 10. 
The stability was evaluated in terms of surface plasmon by 
UV–vis absorption spectrophotometry (figure 3). As can be 
seen in figure 3, Ag@cys nanoparticles are stable over a wide 
pH range. From pH 2 to 5 nanoparticles are well dispersed, as 
revealed by a narrow plasmon, and at pH 6–7 nanoparticles 
get closer but no aggregation takes place, as shown by a lower 
plasmon absorbance at 426 nm while an increase in absorb-
ance is observed in the 600 nm region. At pH 8, the increase in 
absorbance in the 600 nm region turns into a band owing to the 
coupling of adjacent dipolar plasmons [46], as a consequence 
of the lower amount of charged amino groups at this pH. At 
even higher pH values, the net charge is lost completely and 
nanoparticles aggregate and precipitate out of the solution, as 
can be seen from the absence of an absorption peak in the 
plasmon region. Our nanoparticles can therefore be used over 
a fairly ample pH range that includes physiological pH.
The surface modification of nanoparticles with cysteamine 
was also analyzed by Fourier transform infrared (FTIR) 
spectr oscopy and transmission electron microscopy (TEM). 
The comparison between the FTIR spectra of the dialyzed 
Ag@cys nanoparticles and cysteamine hydrochloride (figure 
4) demonstrates the proper surface functionalization of Ag 
nanoparticles with cysteamine: the disappearance of the char-
acteristic SH stretching vibration at 2598 cm−1 in Ag@cys 
proves that the thiol group binds to the nanoparticle surface 
through the sulfur atom. Furthermore, while this vibration is 
still present in Ag@cys prior to the nanoparticle purification 
process due to the excess of unreacted cysteamine hydrochlo-
ride in the reaction medium, it disappears following dialysis 
(figure S1 in supplementary (stacks.iop.org/ANSN/9/015001/
mmedia)). Additionally, the characteristic NH2 bending vibra-
tion at 1589 cm−1 remains in Ag@cys being, in fact, the 
strongest band in the spectrum.
The TEM analysis of Ag@cys nanoparticles revealed that 
they are spherical (figure 5(a)) and crystalline, and all the 
rings could be indexed in the cubic system of metallic silver 
(Fm3m, a  =  0.4 nm; figure 5(b)). In the HRTEM micrograph 
Figure 1. Absorption spectra of products obtained using water 
(dashed line) or DMF (solid line) as solvent for the synthesis of 
cysteamine-capped nanoparticles, after purification. Inset: digital 
photographs of the colloidal suspensions obtained using aqueous 
medium (A) or DMF (B) as solvent.
Figure 2. Schematic representation of cysteamine-capped 
silver nanoparticles with cysteamine in gauche (a) and trans (b) 
conformations.
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shown in figure 5(c) crystalline silver nanoparticles are clearly 
seen and the corresponding (h k l) planes have been marked. 
Finally, figure 5(d) shows an enlargement of a silver nanopar-
ticle oriented along (1 1 1).
Additionally, nanoparticle size was determined both by 
TEM and DLS. According to TEM, their average diameter is 
12 nm, which is in good agreement with the hydrodynamic 
diameter obtained by DLS of 15 nm (figure S2 in supplemen-
tary). Moreover, their zeta potential is extremely high (36 mV 
at pH values up to 5, and remains around 30 mV up to pH 8), 
a fact that is in keeping with good long-term stability. Such a 
high value is also an indicator for a high surface coverage, as 
was confirmed by EDX. In contrast, the reported zeta poten-
tial for the in situ synthesis published in water is just 18.7 mV 
at pH 4 [12], a value far too low for biomedical applications 
(±30 mV), and that necessarily worsens at higher pH values 
given that the zeta potential depends on the charge and the 
amino groups deprotonate at higher pH values. Additionally, 
if we analyze further our results in the light of the reported 
synthesis in water, we find that the initial silver concentra-
tion (~10−5 M [11]) is several orders of magnitude lower than 
the one achieved in our synthesis (0.012 M). Assuming that 
nanoparticles are spherical, as indicated by the TEM images, 







where cM is the molar concentration of AgNO3, MAg is the 
molar mass of silver, r is the average radius of nanoparticles, 
ρ is the density of silver (10.49 g cm−3), and N0 is Avogadro’s 
number. This yields a concentration of silver nanoparticles of 
up to 7.6  ×  10−10 M [11], assuming 100% yield. This com-
pares to our value of 1.7  ×  10−7 M that takes into account the 
yield of the reaction (79%), which means that our concentra-
tion of nanoparticles is at least 220 times higher than the one 
reported in water.
The chemical composition of Ag@cys nanoparticles was 
studied in detail by EDX analysis performed in HAADF-
STEM mode, allowing quantification in very small regions 
to obtain the Ag:S atomic ratio in the nanoparticles. Multiple 
spectra with the beam focused on different silver nanoparti-
cles (figure 6(a)) were recorded to get a faithful representation 
of nanoparticle environments, and a representative spectrum 
is shown in figure 6(b). The average atomic percentage was 
found to be 90.5% silver and 9.5% sulfur.
To determine the Ag:S atomic ratio on the nanoparticle 
surface, an EDX spectrum profile analysis was done, and 
a representative result is shown in figure  7. Twenty spectra 
were recorded along the line profile observed in the HAADF-
scanning image including edges and centers of three nano-
particles (figure 7(a)). The Ag and S profile composition is 
presented in figures 7(b) and (c), respectively, and their atomic 
percentages found at a selection of representative points are 
shown in table 1. Whereas the values at the center of the nan-
oparticles are very similar to the Ag:S ratio average, at the 
edges of the nanoparticles the sulfur percentage increases con-
siderably, reaching values of more than 55%. By combining 
the imaging information with the chemical composition pro-
vided by this technique, it can be concluded that silver nano-
particles are capped with thiol molecules, in agreement with 
the results from FTIR.
Considering that for a particle size of 12 nm approximately 
14% of silver atoms are on the surface, and taking into account 
that the average atomic percentage Ag:S in Ag@cys nanopar-
ticles is 90.5:9.5, it is thus estimated that the cysteamine to 
surface silver ratio is 3:4, i.e. three cysteamine molecules for 
every four silver atoms on the metal surface of nanoparticles. 
This surface coverage is remarkably higher than that obtained 
for other in situ syntheses with other thiols, such as the widely 
employed tiopronin (a tiopronin molecule for every three 
silver atoms on the metal surface of nanoparticles) [49], and 
is in agreement with previous studies on gold showing that 
the self-assembly of cysteamine monolayers on the metal sur-
face is more effective using DMF as solvent than water [50]. 
The surface coverage was calculated by the following equa-
tion with results summarized in table 2
CF =
S(%)
Ag surface of nanoparticle(%)
. (2)
Figure 4. Comparison between the FTIR absorbance spectra 
of dialyzed Ag@cys nanoparticles (black line) and cysteamine 
hydrochloride (blue line). The spectra are normalized with respect 
to the 1589 cm−1 peak.
Figure 3. Absorption spectra of Ag@cys resuspended in water at 
different pH values.
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As shown in table 2, the coverage fraction of cysteamine-
capped silver nanoparticles obtained by our in situ synthesis 
method more than doubles that of the tiopronin-capped nano-
particles, providing increased coating. This is due largely, but 
not exclusively to the reduced bulkiness of cysteamine, as can 
be appreciated from figure S3 (in supplementary) showing the 
Figure 6. Compositional characterization of Ag@cys nanoparticles: (a) HAADF-STEM image showing the positions at which the EDX 
analysis has been done; (b) representative EDX spectrum and the average Ag:S atomic ratio averaged over all positions.
Figure 7. Ag:S profile analysis. (a) HAADF-STEM profile image exploring red and blue points at which the EDX analysis has been done 
along a straight line; (b) and (c) silver and sulfur profile composition, respectively, found by EDX analysis from left to right at the points 
highlighted in red and blue in (a).
Table 1. Ag and S atomic percentages found at a selection of representative points.
Point 2 4 6 8 10 12 15 17 19
Atomic percentage (%) Ag 45.8 91.6 46.6 41.0 82.3 32.3 63.7 90.2 46.1
S 55.2 8.4 53.4 59.0 17.7 67.6 36.3 9.8 53.9
Table 2. Ligand (L) coverage fraction (CF) of Ag@cys 
nanoparticles compared to Ag@tiopronin nanoparticles [49].
L CF
This work Cysteamine 0.76
Castillo et al [49] Tiopronin 0.33
Figure 5. Microstructural characterization of Ag@cys nanoparticles: (a) TEM image; (b) EDX pattern; (c) and (d) HRTEM micrographs.
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solvent-accessible volume. A projection perpendicular to the 
major component of the inertia axis of the molecule yields van 
der Waals areas of 17.9 Å2 and 23.2 Å2 for cysteamine and 
tiopronin, respectively. Moreover, the obtained cysteamine 
coverage means that the total yield of the synthesis as referred 
to the cost-limiting silver is remarkably high, 79%.
3.2. Biological behavior in epidermoid carcinoma cells
New antitumor therapies focus on the targeting of chemothera-
peutic agents to tumor cells to avoid side effects in healthy tis-
sues. To assess whether our nanoparticles can be vectorized to 
specific targets of biomedical interest in cancer therapy, a set 
of nanoparticles was conjugated to an antibody to EGFR. We 
have chosen this receptor because of its relevance in current 
antitumor treatments. EGFR is a transmembrane glycoprotein 
with tyrosine kinase activity, which is involved in the regu-
lation of cellular proliferation, differentiation, and survival, 
playing an important role in the pathogenesis and progression 
of a wide variety of tumors such as gliomas and carcinomas 
of the lung, colon, head and neck, pancreas, ovary, breast, 
bladder, and kidney. For this reason, this receptor has become 
a major target in cancer therapy, both in terms of specific inhi-
bition [51–53] and vectorization [54]. A carbodiimide-medi-
ated coupling reaction was used to conjugate the anti-EGFR 
antibody (Ab) to our cysteamine-capped silver nanoparticles. 
In this reaction, an amide bond is formed between the free 
amine groups of the cysteamine monolayer in Ag@cys and 
the carboxyl terminus of the antibody to yield Ag@cys@Ab 
(scheme 1), ensuring that the orientation of the antibody on 
the nanoparticle surface is appropriate for the interaction with 
its receptor, i.e. the paratope of the antibody remains free. A 
water-soluble carbodiimide, EDC, was used in tandem with 
NHS, to improve the water stability of the carboxylic acid-
activated intermediate [44].
The A431 cell line was chosen as suitable cellular model to 
study the biological behavior of Ag@cys@Ab nanoparticles. 
A431 is an epidermoid carcinoma cell line widely employed 
as model target in the study of therapeutic approaches directed 
to EGFR, owing to the high EGFR expression reported for this 
cell line [55]. The cytotoxicity of Ag@cys@Ab nanoparticles 
was evaluated by resazurin-based in vitro toxicology assay 
following a 48 h exposure to the nanoparticles in concentra-
tions ranging from 5 to 100 µg ml−1. As expected, the delete-
rious effects of silver started to be observable (figure 8) only 
at typical doses previously described for other silver-based 
nanoparticles [56].
Importantly, concentrations below 50 µg nanoparticles 
per ml showed negligible effects on cell viability, thus ren-
dering these particles useful for a number of biological 
applications [57]. For this reason, and in order to study the 
uptake of our targeted nanoparticles, we used a concentra-
tion of 10 µg ml−1 and analyzed via confocal microscopy the 
uptake of these particles after a 48 h incubation period. This 
analysis demonstrated that Ag@cys@Ab nanoparticles could 
be detected both by dark field (figure 9(a)) and fluorescence 
microscopies (figure 9(b)), suggesting feasibility of applica-
tions in theranostics.
Scheme 1. Schematic representation of cysteamine-capped silver nanoparticles functionalized with AlexaFluor488-labelled anti-EGFR 
antibody (Ag@cys@Ab) via carbodiimide-based chemistry (steps 1 and 2), and blockage of unspecific binding sites with BSA (step 3).
Figure 8. Dose-dependent cytotoxicity of Ag@cys@Ab 
nanoparticles in A431 cells (n  =  3; *p  <  0.05).
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4. Conclusions
Our high-yield synthesis method produces highly concen-
trated small (12 nm) and narrow-sized silver nanoparticles, 
whose surfaces are highly decorated with terminal amine 
groups, with an S:Ag ratio as high as 0.76. These nanoparticles 
are stable over a remarkable range of pH values that includes 
physiological pH, with a zeta potential above 30 mV. Both the 
cysteamine to surface silver ratio and the total yield of the syn-
thesis are remarkably higher than those described in the litera-
ture for other thiols. These features make our nanoparticles 
excellent candidates in drug delivery and gene transfection 
applications, as well as in biosensors and chemical sensors. 
Moreover, our synthesis method might be readily extended 
to obtain nanoparticles based on longer chain primary, sec-
ondary, ternary or even quaternary aminethiols, and could also 
be applied to other noble metal nanoparticles, providing an 
improved synthesis method over existing alternatives.
Additionally, we have coupled these nanoparticles to an 
antibody to EGFR, a ‘hot’ target due to its key role in the 
pathogenesis and progression of many solid tumors. These 
targeted nanoparticles have demonstrated both their label-
ling (fluorescence and dark field microscopies) and cytotoxic 
properties in A431 epidermoid carcinoma cells. Our results 
show the feasibility of using cysteamine-capped nanoparti-
cles for therapeutic and diagnostic applications with a great 
potential in anticancer therapies due to the expected cytotoxic 
synergy between cysteamine and silver.
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